Magnolia Medical Technologies, Business Director June 2021-PresentAlabama, Tennessee, Mississippi, Louisiana, and ArkansasInnovative, start-up medical device company focused on the hypergrowth of the Steripath technology to create a new standard of care for the prevention of false-positive blood cultures and to significantly impact patient outcomes to reduce overall hospital costs.- This “hunter” role was designed to execute a top-down/bottom-up sales strategy of a ground floor disposable device to secure implementations and drive adoption in flagship hospitals that would lead to system-wide standardization. This complex process included multiple call points within the hospital, and the primary responsibility was to effectively articulate the clinical and economic value proposition to respective key stakeholders. - Key call points include ED/Emergency Dept, Lab, Infection Prevention, Infectious Disease, ICU/MICU, Antimicrobial Stewardship, Value Analysis, Supply Chain, Channel Partnerships (distributors), and members of the C-Suite (CQO, CNO, CMO, CFO)Awards and Accomplishments:• President’s Award Recipient – 2022• Quota Achievement Award – 2022, 2023• 2x National Business Director of the Quarter (Q1 and Q4 2022)• Revenue Growth Buster Award Q421 (1st eligible quarter with MMT/Immediate impact)• Selected to mentor new Business Directors as company expanded

Responsibility for hospitals and physicians affiliated with interventional radiology, interventional pulmonary, breast surgery, Breast Center‘s, thoracic surgery, and general surgery call points within the state of Alabama. My current product portfolio consists of the following:BARD Biopsy Systems (including Vacuum Assisted devices for breast biopsy), BARD PowerPorts and Apheresis devices, Caterpillar Arteriole Embolization device, Gamma Finder Detection device for sentinel lymph node biopsy/capital equipment, Encore Enspire for stereotactic breast biopsy/capital equipment, PleurX Catheter System, BD Curve (formerly called Denver Shunt)

Interventional Sales Representative responsible for the call points of Cardiothoracic Surgery, Interventional Radiology, and Interventional Pulmonary for the Pleurx Catheter system/Denver Shunt/Temno & Achieve Biopsy System, and diagnostic procedure trays (i.e.: acute drainage, bone marrow biopsy, and other diagnostic procedures performed within radiology).Accepted this expansion territory in 2013; From a catheter perspective, I have significantly grown the base of business from 23/month (when territory was created) to 72/month (thru FY17).• 2017 WINNER’S CIRCLE AWARD HONOREE; Highest ranking award within the company; presented to #1 sales representative in the business unit • FY17 PREIDENT’S CLUB AWARD WINNER• Sales Excellence Award winner for FY17 (>105% to plan of fiscal year); finished 113.58% to plan and $154K growth vs. prior year• Quota Achiever every year since the inception of the territory• Sales Excellence Award winner for FY15 (>105% to plan of fiscal year); Finished #4 overall with respect to percent over quota (GP)• Selected to national Sales Advisory Council for FY16• #1 Chronic Drainage representative for July 2014-June 2015; 1st full year in the field• Partnering4Performance- Inaugural class; hand selected by leadership team to be on a national council for the development and implementation of company business objectives. This process is set up as a career development tool & management training• MPS Sales Process Super User: Selected by leadership team and peers as someone who embraces change and can positively influence others to adapt changes that are made (2016)• Elected member of the Breakfast Club/Skip Level National Round Table with GLOBAL Leadership team; Only 2 representatives from each business unit were selected to participate in this initiative with Bob Roda

Capital and disposable sales of the BARRX Halo Ablation system. This product is used to treat Barrett's esophagus, the precancerous cells that can cause esophageal cancer. By using radiofrequency ablation, the catheter aligned with electrodes is inserted along side of an endoscope and delivers a one second dose of energy to eradicate the Barrett's tissue. This technology is a safe, well-tolerated, and durable treatment for only identifiable landmark that leads to esophageal cancer.

Sales of medical device, capital equipment, diagnostics, Electronic Health Records (EHR) software & Health Information Technology (HIT) in the Alabama marketplace.Core products included:•PADnet for front line arterial testing for the detection & diagnosis of P.A.D (peripheral artery disease), & Chronic Venous Insufficiency. Call points included Cardiologists, Nephrologists, Endocrinologists, Podiatrists, Internists, & General Practitioners. •Podiatric specific electronic medical records (TRAKnet DPM). Responsibilities include selling in a competitive marketplace & consulting Alabama Podiatrists with respect to implementing an ONC-ATCB certified Electronic Health Records that supports “Meaningful Use”•PADnet2.0 Disease Management Software for hospitals & Interventional Cardiologists/Vascular Surgeons to build a long term sustainable referral network for P.A.D. within a designated community. Primary call points were Interventional Cardiologists, Interventional Radiologists, & Vascular SurgeonsAccomplishments:•Ranked #3 in the company for 2011•Presidents Club Winner in 1st year of device sales•Selected as a member of the “Tips From The Top” panel at National Sales Meeting 2012•Exceeded quota on all core products in 2011•145.10% to quota for Overall Goal in 2011•148% to quota for PADnet goal in 2011•142% to quota for TRAKnet goal in 2011•Sold 27 devices in the territory over 10 months (highest in the company for 2011 calendar year)•Contests & Awards: Presidents Club 2011; Core Product Bonus (>130% of core products); Winner of 5 for 5 contest in May (5 PADnet Devices placed in one month); “PADnet Placement Bonus” at 2012 NSM; Q4 2011 TriFecta Bonus (125% of quota each month in 4th quarter); Fast Start Contest Winner January 2012 (200% of quota)

Accepted as a promotional position after only 23 months with the company & relocated from Dallas, TX. Territory was composed of all specialists within the cardiovascular arena in all of Central Alabama & North Alabama. Responsibilities included 130 physicians (Tier 1-3) including reach to only Cardiologists, Nephrologists, Endocrinologists, & Hypertension SpecialistsAccomplishments:• Inherited territory ranked last (43) with one trimester left in 07’; Ranked 4 out of 43 in T307, increasing overall YTD rank to 33 & demonstrated immediate impact• Ranked #4 of 30 among CM1 in Region in 2010 and #8 of 58 among CM1 & CM2 overall• Ranked #6 of 23 YTD2009 (moved up from 12 of 23 at year beginning)• Contests & Awards: Fast Start Q1 2010-Winner (Launch Product/VALTURNA); Start to Finish 2008-Winner; Capture Cozaar Contest-Winner; POD of the Quarter 2Q08; Managers Tiger Award received for greatest improvement in rank for 2008

Largest geographical territory in Dallas where time management, territory planning, & Medicaid pull-through were critical in the success for our District. Responsibilities included 158 physicians (Tier 1-3) including reach to Family Practice, Internal Medicine, Cardiology, & Gastroenterologists (& corresponding GI labs) selling the antihypertensive portfolio & Zelnorm.Accomplishments:• Selected for the Regional Managers “Director’s Award” for T1 2006 (Trimester 1)• Selected for Representative of the Quarter from a large FAP office (9 doctors, 2 PA’s, 28 employees) based on voting system involving the entire organization; Aug 2006• Increased MIR ranking for lead product from 89.05% in T106 to 114.52% in T206• Recognized at National Sales Meeting 06’ for “Highest Increase in Ranking”; Moved Nat’l Rank from 445 to 129 out of 511 reps from T106-T206 for lead product (316 spots)• Increased National Ranking 277 spots from 421 to 144 out of 511 reps between T106-T206 for total product portfolio• Highest QTQ in District awarded for EVERY trimester in 2006 (reach & frequency); Highest Daily Call Average awarded for both first & third trimesters of 2006

Promoted to cardiovascular hospital representative for OKC after only 7 months in the previous territory. Account responsibilities included 2 local teaching institutions, 4 VA’s, 3 Air Force Bases (Tinker/Sheppard/Altus), Ft Sill/Reynolds Army Hospital, & 4 Indian Health hospitals. In addition to the staff physicians at the area DOD accounts, my call points included over 160 residents/fellows in the field of Cardiology, Nephrology, Endocrinology, Internal Medicine, Family Practice & Geriatric Medicine.Accomplishments:• IHR of the first semester of 2005 (#1 in the region, #3 in the country)• IHR of the first quarter of 2005 (#1 in the region, #15 in the country)• Engendered formulary additions of Inspra on Oklahoma State Medicaid, Saint Anthony’s Hospital (largest CHF clinic in territory), Oklahoma City VA (as a non-formulary request), & University Hospital in April 2005• Engendered formulary additions of Caduet on Oklahoma Medicaid & Community Care• Saved Lipitor’s status as “preferred” on Oklahoma State Medicaid by utilizing a key opinion leader to speak to the DUR Board in third quarter of 2004• Cultivated & Developed 12 new promotional speakers for product positioning in the 15 months I was in the territory (Faculty, Residents, & Fellows)

Territory Landscape:•Last in district in terms of volume rank; first in district in terms of share rank•Extremely large penetration of Medicaid (60%); Norvasc market share was over 13%•Responsible for the satellite VA Clinic of Audie L. Murphy Veterans Hospital located in McAllen, Texas•Responsibilities also included the University of Texas Health Science Center Family Practice Residency Program•Hospital and long term care experience included McAllen Medical Center, Rio Grande Regional Hospital, McAllen Heart Hospital, Edinburg Regional Hospital, Mission Hospital, Rio Grande City General Hospital, APS-Omnicare Long term care, and 4 area cath labsAccomplishments:•Circle of Excellence, 2001- Started #53 in region on February GAR/Finished at #7 in region as measured by the December GAR•Rookie of the Year, 2001•Adventures in Achievement/Blockbuster Performance Contest winner 2001•District Representative of the Quarter, Third Quarter 2001•District Representative of the Quarter, Second Quarter 2002•January 2003 GAR was 64/68 @ 88.58% and moved up to 26/68 @ 98.83% on the June GAR with respect to Norvasc prior to leaving territory to relocate to Victoria•Selected as guest trainer for Phase 2B for the week of November 9th-November 14th, 2003 at the Pfizer Learning Center in Rye Brook, New York•District Representative of the Quarter, Third Quarter 2003•Lipitor market share jumped from 28% to 34.9% to surpass Zocor for the first time among cardiologists in Victoria the third month I was in the territory•Won the district contest “Double Trouble” in the month of September which exemplifies the least amount of market penetration for the competitive products of Levitra and Crestor

Responsibilities included selling specialty petroleum products in a dynamic and diverse marketplace, cold calling, and implementing other various added service programs to obtain new business and increase the numbers on that of existing customers.• Established only existing national account at J.A.M Distributing Co. (Trinity Industries)• Reached salary plus commission in the accelerated time period of eleven months by increasing the number of active accounts in an under developed territory• Tripled salary in the month of September 1999• Increased overall sales by 40% in 1999• Maintained and serviced largest account out of Dallas division• Selected to attend The Exxon/Mobil Distributing Training program (only 2 per year are selected)• Customers included Allied Signal, Miller Brewing (Brewery), Halliburton Energy Services, Trinity Industries, Freightliner, International, Sterilite Corporation, Raytheon